What is the current valuation of the Antipsychotic Drugs Market?

The Antipsychotic Drugs Market was valued at 17.49 USD Billion in 2024. Read More

What is the projected market valuation for the Antipsychotic Drugs Market in 2035?

The market is projected to reach 39.32 USD Billion by 2035. Read More

What is the expected CAGR for the Antipsychotic Drugs Market during the forecast period 2025 - 2035?

The expected CAGR for the Antipsychotic Drugs Market during 2025 - 2035 is 7.64%. Read More

Which companies are considered key players in the Antipsychotic Drugs Market?

Key players include Johnson & Johnson, Pfizer, Roche, Eli Lilly and Company, and AstraZeneca. Read More

What was the market size for Atypical Antipsychotics in 2024?

In 2024, the market size for Atypical Antipsychotics was 7.0 USD Billion. Read More

What is the projected market size for Schizophrenia treatment by 2035?

The projected market size for Schizophrenia treatment is expected to reach 11.75 USD Billion by 2035. Read More

How does the market size for Adult patients compare to Geriatric patients in 2024?

In 2024, the market size for Adult patients was 10.0 USD Billion, compared to 4.99 USD Billion for Geriatric patients. Read More

What is the expected growth for Long-acting Injectables in the Antipsychotic Drugs Market?

The market for Long-acting Injectables is projected to grow from 3.0 USD Billion in 2024 to 7.0 USD Billion by 2035. Read More

What is the anticipated market size for Injectable administration routes by 2035?

The anticipated market size for Injectable administration routes is expected to reach 10.5 USD Billion by 2035. Read More

Antipsychotic Drugs Market

Q: What are the market segments based on drug type in the Antipsychotic Drugs Market?

The market segments include Typical Antipsychotics, Atypical Antipsychotics, Long-acting Injectables, and Mood Stabilizers. Read More

Antipsychotic Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Typical Antipsychotics, Atypical Antipsychotics, Long-acting Injectables, Mood Stabilizers), By Indication (Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Autism Spectrum Disorders), By Administration Route (Oral, Injectable, Transdermal), By Patient Age Group (Pediatric, Adult, Geriatric) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.64%

2024 Market Size

$ 17.49 Billion

2035 Market Size

$ 39.32 Billion

Pharmaceutical ● Updated May 2026 Report ID: MRFR/Pharma/2067-HCR | Pages: 90 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Typical Antipsychotics | |
  2. 4.1.2 Atypical Antipsychotics | |
  3. 4.1.3 Long-acting Injectables | |
  4. 4.1.4 Mood Stabilizers |
2. 4.2 Healthcare, BY Indication (USD Billion) | |
  1. 4.2.1 Schizophrenia | |
  2. 4.2.2 Bipolar Disorder | |
  3. 4.2.3 Major Depressive Disorder | |
  4. 4.2.4 Autism Spectrum Disorders |
3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Injectable | |
  3. 4.3.3 Transdermal |
4. 4.4 Healthcare, BY Patient Age Group (USD Billion) | |
  1. 4.4.1 Pediatric | |
  2. 4.4.2 Adult | |
  3. 4.4.3 Geriatric |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Johnson & Johnson (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Pfizer (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Eli Lilly and Company (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Bristol-Myers Squibb (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Novartis (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Sanofi (FR) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Otsuka Pharmaceutical (JP) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies | |
  10. 5.2.10 Merck & Co. (US) | | |
    1. 5.2.10.1 Financial Overview | | |
    2. 5.2.10.2 Products Offered | | |
    3. 5.2.10.3 Key Developments | | |
    4. 5.2.10.4 SWOT Analysis | | |
    5. 5.2.10.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY INDICATION |
8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
9. 6.6 US MARKET ANALYSIS BY PATIENT AGE GROUP |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY INDICATION |
12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT AGE GROUP |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY INDICATION |
17. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT AGE GROUP |
19. 6.16 UK MARKET ANALYSIS BY TYPE |
20. 6.17 UK MARKET ANALYSIS BY INDICATION |
21. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
22. 6.19 UK MARKET ANALYSIS BY PATIENT AGE GROUP |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY INDICATION |
25. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT AGE GROUP |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY INDICATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT AGE GROUP |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY INDICATION |
33. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT AGE GROUP |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY INDICATION |
37. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT AGE GROUP |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT AGE GROUP |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY INDICATION |
46. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT AGE GROUP |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY INDICATION |
50. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT AGE GROUP |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY INDICATION |
54. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT AGE GROUP |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY INDICATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT AGE GROUP |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY INDICATION |
66. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT AGE GROUP |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY INDICATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT AGE GROUP |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY INDICATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT AGE GROUP |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY INDICATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT AGE GROUP |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY INDICATION |
83. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT AGE GROUP |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY INDICATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT AGE GROUP |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT AGE GROUP |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT AGE GROUP |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT AGE GROUP |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY INDICATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT AGE GROUP |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY INDICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY PATIENT AGE GROUP, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Antipsychotic Drugs Market Segmentation

Antipsychotic Drugs Market By Type (USD Billion, 2025-2035)

Typical Antipsychotics
Atypical Antipsychotics
Long-acting Injectables
Mood Stabilizers

Antipsychotic Drugs Market By Indication (USD Billion, 2025-2035)

Schizophrenia
Bipolar Disorder
Major Depressive Disorder
Autism Spectrum Disorders

Antipsychotic Drugs Market By Administration Route (USD Billion, 2025-2035)

Oral
Injectable
Transdermal

Antipsychotic Drugs Market By Patient Age Group (USD Billion, 2025-2035)

Pediatric
Adult
Geriatric

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”